C WorldWide Group Holding A S Decreases Stock Holdings in Natera, Inc. $NTRA

C WorldWide Group Holding A S reduced its position in shares of Natera, Inc. (NASDAQ:NTRA) by 14.5% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 118,000 shares of the medical research company’s stock after selling 20,000 shares during the quarter. Natera makes up about 0.8% of C WorldWide Group Holding A S’s holdings, making the stock its 20th biggest holding. C WorldWide Group Holding A S’s holdings in Natera were worth $32,031,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in NTRA. California State Teachers Retirement System increased its position in shares of Natera by 28,373.5% in the second quarter. California State Teachers Retirement System now owns 56,324,789 shares of the medical research company’s stock valued at $15,289,364,000 after acquiring an additional 56,126,974 shares during the period. BlackRock Inc. purchased a new position in Natera during the 2nd quarter valued at about $2,962,770,000. Coatue Management LLC lifted its holdings in Natera by 1,446.1% in the 4th quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company’s stock worth $603,270,000 after buying an additional 2,463,008 shares during the period. Wellington Management Group LLP lifted its holdings in Natera by 94.7% in the 4th quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company’s stock worth $1,140,026,000 after buying an additional 2,420,263 shares during the period. Finally, Norges Bank bought a new stake in shares of Natera in the 4th quarter worth approximately $372,398,000. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Natera Trading Down 1.2%

NTRA opened at $324.14 on Wednesday. The company has a market cap of $46.72 billion, a price-to-earnings ratio of -238.34 and a beta of 1.54. The stock has a fifty day simple moving average of $294.79 and a two-hundred day simple moving average of $239.44. Natera, Inc. has a 12-month low of $157.43 and a 12-month high of $343.18.

Natera (NASDAQ:NTRA) last released its earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.02. The firm had revenue of $752.75 million for the quarter, compared to the consensus estimate of $661.24 million. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The company’s revenue was up 37.7% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.74) EPS. On average, analysts predict that Natera, Inc. will post -1.02 EPS for the current year.

Wall Street Analyst Weigh In

NTRA has been the subject of a number of research analyst reports. UBS Group set a $260.00 price target on Natera in a research note on Wednesday, June 24th. Weiss Ratings reissued a “sell (d-)” rating on shares of Natera in a research report on Friday, July 17th. Barclays restated an “overweight” rating and issued a $340.00 price objective on shares of Natera in a report on Friday, August 7th. Canaccord Genuity Group set a $375.00 target price on shares of Natera in a research report on Friday, August 7th. Finally, Wolfe Research started coverage on shares of Natera in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $260.00 target price on the stock. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $322.50.

Insider Buying and Selling

In other Natera news, CFO Michael Brophy sold 478 shares of Natera stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $274.22, for a total transaction of $131,077.16. Following the completion of the transaction, the chief financial officer owned 51,637 shares in the company, valued at approximately $14,159,898.14. The trade was a 0.92% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Steven Chapman sold 1,698 shares of the business’s stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $320.99, for a total value of $545,041.02. Following the completion of the sale, the chief executive officer directly owned 98,199 shares in the company, valued at $31,520,897.01. This trade represents a 1.70% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 71,206 shares of company stock worth $19,944,069. 5.05% of the stock is currently owned by corporate insiders.

Natera Profile

Natera, Inc is a diagnostic company that develops and commercializes molecular testing services based on cell-free DNA and other genetic technologies. The company’s tests are designed to help clinicians assess genetic and reproductive health, monitor organ transplants, and detect and track cancer.

Its principal products include Panorama, a noninvasive prenatal screening test; Horizon, a carrier screening test; Signatera, a personalized circulating tumor DNA test used in cancer monitoring; and Prospera, a molecular test intended to help assess the risk of organ transplant rejection.